Venous Thrombosis in Cancer Patients: Insights from the FRONTLINE Survey

Kakkar, Ajay K.; Levine, Mark; Pinedo, H.M.; Wolff, Robert A.; Wong, John

doi:10.1634/theoncologist.8-4-381

Cited by 197 publications

(140 citation statements)

References 19 publications

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…Consistent with previous studies, in our study we observed the highest VTE rates in patients with brain tumors (high grade glioma) [30]. However, we did not find higher MP levels in the subgroup of patients with brain tumors compared to other tumor entities.…”

Section: Discussionsupporting

confidence: 92%

Circulating procoagulant microparticles in cancer patients

Thaler

Weinstabl

et al. 2010

Ann Hematol

View full text Add to dashboard Cite

Accumulating evidence indicates that microparticles (MPs) are important mediators of the interaction between cancer and the hemostatic system. We conducted a large prospective cohort study to determine whether the number of circulating procoagulant MPs is elevated in cancer patients and whether the elevated MP levels are predictive of occurrence of venous thrombembolism (VTE). We analyzed plasma samples of 728 cancer patients from the ongoing prospective observational Vienna Cancer and Thrombosis Study (CATS). Study endpoint was the occurrence of symptomatic VTE. Sixty-five age-and sex-matched healthy controls were recruited for defining the cut-off point for elevated MPs (4.62 nanomolar phosphatidylserine nM PS ), which was set at the 95th percentile of MP levels in healthy controls. The measurement of MPs was performed after capture onto immobilized annexin-V, and determination of their procoagulant activity was quantified with a prothrombinase assay. During a median observation period of 710 days 53 patients developed VTE. MP levels (nM PS) were significantly higher in cancer patients than in healthy controls (median 25th-75th percentile : 3.95 1.74-7.96 vs. 1.19 0.81-1.67 , p<0.001). Multivariate analysis including age, sex, surgery, chemo-and radiotherapy showed no statistically significant association of the hazard ratio of elevated MPs with VTE (0.95 [95% CI: 0.55-1.64], p=0.856). In conclusion, MP levels were elevated in cancer patients compared to healthy individuals in this study. However, elevated MP levels were not predictive of VTE.

show abstract

Section: Discussionsupporting

confidence: 92%

Circulating procoagulant microparticles in cancer patients

Thaler

Weinstabl

et al. 2010

Ann Hematol

View full text Add to dashboard Cite

show abstract

“…It has been estimated that one in seven hospitalized cancer patients who succumb to their disease do so from pulmonary embolism [4]. Of these patients, 60% have localized cancer or limited metastatic disease, which would have allowed for longer survival in the absence of a fatal embolic event.…”

Section: Introductionmentioning

confidence: 99%

Nonbacterial Thrombotic Endocarditis in Cancer Patients: Pathogenesis, Diagnosis, and Treatment

2007

View full text Add to dashboard Cite

LEARNING OBJECTIVES1. Enumerate procoagulant factors present in malignancy and the risk for thromboembolic events.2. Describe the morbidity associated with nonbacterial thrombotic endocarditis.3. List the recommended evaluations and treatments for nonbacterial thrombotic endocarditis.Access and take the CME test online and receive 1 AMA PRA Category 1 Credit ™ at CME.TheOncologist.com CME CME ABSTRACTThrombophilia is a well-described consequence of cancer and its treatment. The pathogenesis of this phenomenon is complex and multifactorial. Nonbacterial thrombotic endocarditis (NBTE) is a serious and potentially underdiagnosed manifestation of this prothrombotic state that can cause substantial morbidity in affected patients, most notably recurrent or multiple ischemic cerebrovascular strokes. Diagnosis of NBTE requires a high degree of clinical suspicion as well as the judicious use of two-dimensional echocardiography to document the presence of valvular thrombi. In the absence of contraindications to therapy, treatment consists of systemic anticoagulation, which may ameliorate symptoms and prevent further thromboembolic episodes, as well as control of the underlying malignancy whenever possible. The Oncologist 2007;12:518 -523 Disclosure of potential conflicts of interest is found at the end of this article.

show abstract

“…One of the most serious complications posed by an implanted port system is the appearance of port-induced sepsis [13,14]. It is also known that an advanced degree of metastasis or malignant tumor with a high one-year mortality rate (e. g. pancreatic cancer) entails elevated thrombophilia [15,16], which can in turn increase the risk of catheter lumen occlusion. This retrospective study aims to evaluate correlations between underlying disease and port complications.…”

mentioning

confidence: 99%

Evaluation of Correlations between Underlying Disease and Port Complications

Teichgräber¹,

Nagel²,

Kausche³

2014

Fortschr Röntgenstr

View full text Add to dashboard Cite

Purpose: Evaluation of correlations between underlying disease and port complications. Materials and Methods: Retrospective analysis of a data set of 3160 port systems, which had been interventionally implanted over a period of 10 years. Of these, 1393 were included in the final evaluation. The 7 most common underlying diseases and port-induced complications were considered. Port-related thrombotic events, port pocket infections as well as the port-induced sepsis were evaluated and classified as either early or late complications. Results: In 1393 ports, 131 experienced complications. Of these, 22.1?% (n?=?29) were early and 79.6?% (n?=?102) late complications. The overall incidence rate of late complications was 0.253/1000 observed days. It differed significantly between the underlying diseases (p?

show abstract

Venous Thrombosis in Cancer Patients: Insights from the FRONTLINE Survey

Cited by 197 publications

References 19 publications

Circulating procoagulant microparticles in cancer patients

Circulating procoagulant microparticles in cancer patients

Nonbacterial Thrombotic Endocarditis in Cancer Patients: Pathogenesis, Diagnosis, and Treatment

Evaluation of Correlations between Underlying Disease and Port Complications

Contact Info

Product

Resources

About